ArticleAmerican journal of translational research2016
Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Prognostic and Predictive Value ofFrontiers in endocrinology · 2022Pooled it
- Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).Breast (Edinburgh, Scotland) · 2026Trial
- Trial
- Profiling mRNA and miRNA expression variations associated with cyclin-dependent kinase pathway in the low-grade luminal early breast cancer.Journal of applied genetics · 2025Article
- Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update.International journal of molecular sciences · 2025Review
- Sequential activation of ERα-AMPKα signaling by the flavonoid baicalin down-regulates viral HNF-dependent HBV replication.Acta pharmacologica Sinica · 2025Article
- Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.Breast cancer research and treatment · 2025Article
- Article
- ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy.International journal of nanomedicine · 2023Article
- Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women.Archives of Iranian medicine · 2022Article
- High expression of Rab31 confers a poor prognosis and enhances cell proliferation and invasion in oral squamous cell carcinoma.Oncology reports · 2021Observational
- High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer.OncoTargets and therapy · 2021Article
- Chaperonin-Containing TCP1 Complex (CCT) Promotes Breast Cancer Growth Through Correlations With Key Cell Cycle Regulators.Frontiers in oncology · 2021Article
- Let-7b downgrades CCND1 to repress osteogenic proliferation and differentiation of MC3T3-E1 cells: An implication in osteoporosis.The Kaohsiung journal of medical sciences · 2020Article
- Article
- Research Progress of Sirtuin4 in Cancer.Frontiers in oncology · 2020Review
- SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.Cancer medicine · 2019Article
- Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters.African health sciences · 2019Article
- Article
- Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.PloS one · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCND1 is amplified in around 10-20% of primary breast cancers and preferentially occurs in ER positive tumors. Though CCND1 amplification was reported predicting poor response of adjuvant tamoxifen treatment and poor prognosis in ER positive breast cancers, there were controversial data regarding the predicting value of CyclinD1 protein overexpression. In this study, we detected CyclinD1 expression using immunohistochemistry and CCND1 gene copy number using fluorescence in situ hybridization (FISH) in 355 invasive breast cancers with foci ductal carcinoma in situ (DCIS). CCND1 amplification was founded in 52 (14.6%) cases all of which showed moderate to strong CyclinD1 expression. However, majority of CCND1- tumors exhibited mild to moderate CyclinD1 staining. There were identical alterations in DCIS and the invasive lesions within the same tumor. CCND1 amplification was positively correlated with ER, PR and lymph node status (P<0.001) while negatively correlated with HER-2 amplification and p53 status (P<0.05). The majority of the CCND1 amplification/high CyclinD1 breast cancers were luminal B type while basal-like type often lost the expression of this protein. The ROC curve analysis showed that a cut-off point at which the immunostaining score of CyclinD1 is 6.5 could predict CCND1 gene amplification in breast cancer. This study indicated loss expression of CyclinD1 might be an important event in the tumorigenesis in basal-like breast cancers. Further, we confirmed an optimal cut-off point of immunostaining scores of CyclinD1 protein which could be used to predict the status of CCND1 gene and identify a subgroup of ER positive breast cancers with poor response to endocrine agents.
Indexed as
Identifiers
27069548PMC4759424W2419243182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.